AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor...

Related Keywords

Puerto Rico ,United States ,America ,American ,Jessica Akopyan ,Davidm Reese ,Prevalence Estimates For Selected Health Outcomes ,Instagram ,Amgen ,National Health ,Linkedin ,Twitter ,National Health Statistics ,Public Health ,Therapeutics Inc ,Prepandemic Data Files Development Of ,Teneobio Inc ,Nutrition Examination ,Nutrition Examination Survey ,Centers For Disease ,Kyowa Kirin Co Ltd ,World Health Organization ,Most Sustainable Companies ,Beigene Ltd ,Exchange Commission ,Youtube ,American Medical Association ,World Congress ,European Health Commission ,Chemocentryx Inc ,Body Weight ,Highest Dose After ,Insulin Resistance ,Cardiovascular Disease ,Body Mass Index ,Dow Jones Industrial Average ,Five Prime Therapeutics ,Data Files Development ,Prevalence Estimates ,Selected Health ,National Health Statistics Reports ,Disease Control ,Accessed November ,Silver Spring ,Multiple Ascending Dose Study ,Participants With ,